NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Jan Drappatz
AD Scientific Index 2024
Medical and Health Sciences / Neurology
University of Pittsburgh - Pittsburgh / United States
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Jan Drappatz's MOST POPULAR ARTICLES
1-)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTT Batchelor, AG Sorensen, E di Tomaso, WT Zhang, DG Duda, ...Cancer cell 11 (1), 83-95, 200720012007
2-)
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceAD Norden, GS Young, K Setayesh, A Muzikansky, R Klufas, GL Ross, ...Neurology 70 (10), 779-787, 20089282008
3-)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialM Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ...The Lancet Oncology 18 (10), 1373-1385, 20177112017
4-)
Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTT Batchelor, DG Duda, E di Tomaso, M Ancukiewicz, SR Plotkin, ...Journal of Clinical Oncology 28 (17), 2817-2823, 20105672010
5-)
Differential sensitivity of glioma-versus lung cancer–specific EGFR mutations to EGFR kinase inhibitorsI Vivanco, HI Robins, D Rohle, C Campos, C Grommes, PL Nghiemphu, ...Cancer discovery 2 (5), 458-471, 20123722012
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept